Vidupiprant API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Vidupiprant API 1169483-24-2?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Vidupiprant. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Vidupiprant
- Synonyms:
- Cas Number:
- 1169483-24-2
- DrugBank number:
- DB12272
- Unique Ingredient Identifier:
- 61OTZ32XNC
General Description:
Vidupiprant, identified by CAS number 1169483-24-2, is a notable compound with significant therapeutic applications. Vidupiprant has been used in trials studying the treatment and basic science of Asthma.
Classification:
Vidupiprant belongs to the class of organic compounds known as diphenylethers. These are aromatic compounds containing two benzene rings linked to each other through an ether group, classified under the direct parent group Diphenylethers. This compound is a part of the Organic compounds, falling under the Benzenoids superclass, and categorized within the Benzene and substituted derivatives class, specifically within the Diphenylethers subclass.
Categories:
Vidupiprant is categorized under the following therapeutic classes: Acids, Carbocyclic, Amides, Sulfones, Sulfur Compounds. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Vidupiprant is a type of Anti-asthma
Anti-asthma pharmaceutical APIs are a category of active pharmaceutical ingredients (APIs) specifically developed to combat asthma, a chronic respiratory condition characterized by inflammation and narrowing of the airways. These APIs play a crucial role in the formulation of effective medications used to manage and treat asthma symptoms.
The primary objective of anti-asthma pharmaceutical APIs is to alleviate airway inflammation and bronchospasms, which are the major factors contributing to asthma attacks. These APIs target specific cellular receptors involved in the inflammatory response, such as leukotriene receptors and beta-2 adrenergic receptors.
Corticosteroids are a common class of anti-asthma APIs used to suppress inflammation in the airways. They work by inhibiting the production of inflammatory molecules, thereby reducing swelling and mucus production. Beta-2 agonists are another essential group of APIs that act on the beta-2 adrenergic receptors in the airway smooth muscles, leading to relaxation and opening of the airways.
Anti-asthma APIs are carefully synthesized and purified to meet stringent quality standards, ensuring their safety and efficacy. Extensive research and development efforts go into optimizing the pharmacological properties of these APIs, including their bioavailability, stability, and compatibility with different formulations.
Pharmaceutical companies utilize anti-asthma APIs to develop various dosage forms, including inhalers, tablets, and injections. These APIs are often combined with other excipients and technologies to enhance drug delivery and improve patient compliance.
In conclusion, anti-asthma pharmaceutical APIs are critical components in the development of medications that effectively manage asthma symptoms. They target key mechanisms underlying asthma pathophysiology, providing relief from airway inflammation and bronchospasms. These APIs enable the formulation of safe and efficient anti-asthma drugs, empowering individuals with asthma to lead healthier lives.
